Upadacitinib for Refractory Alopecia Areata Unresponsive to Prior Systemic Therapies: A Retrospective Study

Supplemental figure I showing the efficacy of Upadacitinib; Supplemental table Idetailing baseline SALT scores, changes in SALT scores, and serum IgE levels for each patient with refractory alopecia areata following treatment with Upadacitinib; Supplementary Table II. Correlation between characteristics of alopecia areata patients treated with upadacitinib and percentage of hair regrowth at week 24w.补充图I展示乌帕替尼（Upadacitinib）的临床疗效；补充表I详细列明了接受乌帕替尼治疗的各例难治性斑秃（refractory alopecia areata）患者的基线SALT评分（SALT score）、SALT评分变化值以及血清免疫球蛋白E（IgE）水平；补充表II：接受乌帕替尼治疗的斑秃（alopecia areata）患者的临床特征与第24周毛发再生率之间的相关性。